Rindlisbacher B, et al. - Metabolic signatures might indicate pathological pathways involved in idiopathic pulmonary fibrosis (IPF) development and progression. Reliable serum biomarker would help to improve both diagnostic approach and monitoring of drug effects. In this study, researchers compared the global metabolic profiles measured by ultra high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) of stable IPF patients with that of healthy participants and identified a lysophosphatidylcholine (LysoPC) as a potential biomarker in the serum of patients with IPF.